University of Minnesota - Masonic Cancer Center
Minneapolis, MN
Not yet accepting
QUINTESSENTIAL-2
Phase 3 Clinical Trial Comparing the Safety and Efficacy of BMS-986393 to Standard of Care Regimens in Patients with Relapsed/Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Randomization
- Phase 3
- CAR T Cell
- BCMA
- CD19
- Phase 1/2
- Has results
Accepting patients
IDP-023
Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Natural Killer Cells (Allogeneic)
- Phase 1/2
Accepting patients
Post-Transplant Cytoxan
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
- Allogeneic Stem Cell Transplant
- Xanthine Oxidase Inhibitor
- Phase 2
Accepting patients
Myeloablative Allo Stem Cell Transplant
Myeloablative Allogeneic Hematopoietic Stem Cell Transplant With Related or Unrelated Donor for Hematological Disorders
- Allogeneic Stem Cell Transplant
- Phase 2
1 hidden based on your filters.Show All